EP0832219A2 - Leptine chimirasee par fusion avec un domaine d'immunoglobuline et utilisation correspondante - Google Patents

Leptine chimirasee par fusion avec un domaine d'immunoglobuline et utilisation correspondante

Info

Publication number
EP0832219A2
EP0832219A2 EP96917584A EP96917584A EP0832219A2 EP 0832219 A2 EP0832219 A2 EP 0832219A2 EP 96917584 A EP96917584 A EP 96917584A EP 96917584 A EP96917584 A EP 96917584A EP 0832219 A2 EP0832219 A2 EP 0832219A2
Authority
EP
European Patent Office
Prior art keywords
leptin
chimera
human
variant
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96917584A
Other languages
German (de)
English (en)
Inventor
Michael Joseph SmithKline Beecham Pharm. BROWNE
Conrad Gerald SmithKline Beecham Pharm. CHAPMAN
Helen Elizabeth SmithKline Beecham CLINKENBEARD
Jeffrey Hugh SmithKline Beecham Pharm. ROBINSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP0832219A2 publication Critical patent/EP0832219A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention relates to a novel compound being a novel chimeric protein, to a process for the preparation of such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound in medicine, especially for the treatment of obesity and associated diseases.
  • European Patent Application, Publication number 0 464 533 discloses fusion proteins comprising various portions of the constant region of immunoglobulin molecules together with another human protein or part thereof.
  • European Patent Application, Publication number 0 297 882 discloses fusion proteins comprising various portions of the plasminogen molecule with part of another human protein.
  • Zhang et al. (Nature: 372, 425 - 432; 1994) describe the positional cloning of a mouse obese gene and its human homologue.
  • the sequence of the Open Reading Frame (ORF) of the mouse gene predicts a polypeptide of 167 amino acids and Zhang et al. predicted the presence of a signal sequence which would lead to the production of a mature protein of 146 residues.
  • the human homologue was disclosed as having a similar size of 146 amino acids for the mature protein.
  • a pa ⁇ icularly desirable property of an obesity agent is a clearance rate in humans commensurate with patient acceptable treatment regimens, especially regimens for injectable therapies.
  • Zhang et al. do not disclose information relating to the clearance rate of the active molecule in either mouse or humans.
  • leptin must interact with one or more receptors in the brain.
  • chimeric derivatives of leptin which surprisingly, despite their large molecular size, have good pharmacological activity combined with prolonged clearance rates. These chimeric derivatives of leptin are therefore indicated to be particularly useful for the treatment or prophylaxis of obesity and for the treatment or prophylaxis of diseases and conditions associated with obesity, such as atherosclerosis, hypertension and, especially, Type II diabetes. In pa ⁇ icular these compounds are considered to be useful for administration by injection. These compounds are also considered to be useful in cosmetic treatments for the improvement of body appearance.
  • the invention provides a chimeric leptin or a chimeric mutant or derivative of leptin.
  • a chimeric leptin is a protein comprising leptin or a mutant or variant thereof fused to a human immunoglobulin domain or a mutant or variant thereof.
  • the chimeric protein comprises one human immunoglobulin domain.
  • the human immunoglobulin domain is fused to the C-terminus of leptin.
  • One favoured human immunoglobulin is an human immunoglobulin Fc domain.
  • An example of a human immunoglobulin Fc domain is an IgG4PE variant in pa ⁇ icular IgG4 hinge-CH 2 -CH 3 .PE.
  • Other examples are IgG4, IgGl and IgGlGT, in particular the hinge-CH2-CH3 region in each case.
  • mutant or variant used with respect to a pa ⁇ icular protein encompasses any molecule such as a truncated or other derivative of the relevant protein which retains substantially the same activity in humans as the relevant protein.
  • Such other derivatives can be prepared by the addition, deletion, substitution, or rearrangement of amino acids or by chemical modifications thereof.
  • the immunoglobulin may be of any subclass (IgG, IgM, IgA, IgE), but is preferably IgG, such as IgGl, IgG3 or IgG4.
  • the said constant domain(s) or fragment thereof may be derived from the heavy or light chain or both.
  • the invention encompasses mutations in the immunoglobulin component which eliminate undesirable prope ⁇ ies of the native immunoglobulin, such as Fc receptor binding and/or introduce desirable prope ⁇ ies such as stability. For example, Angal S., King D.J., Bodmer M.W., Turner A., Lawson A.D.G., Robe ⁇ s G., Pedley B.
  • EP0307434 discloses various mutations including an L to E mutation at residue 248 (Kabat numbering) in IgG.
  • the constant domain(s) or fragment thereof is preferably the whole or a substantial pan of the constant region of the heavy chain of human IgG.
  • the IgG component suitably comprises the CH2 and CH3 domains and the hinge region including cysteine residues contributing to inter-heavy chain disulphide bonding.
  • the IgG component when the IgG component is derived from IgG4 it includes cysteine residues 8 and 11 of the IgG4 hinge region (Pinck J.R. and Milstein C, Nature vo!216pp941-942, 1967).
  • the IgG4 component consists of amino acids co ⁇ esponding to residues 1-12 of the hinge, 1-110 of CH2 and 1-107 of CH3 of IgG4 described by Ellison J., Buxbaum J. and Hood L., DNA vollppl 1-18, 1981.
  • residue 10 of the hinge is altered from serine (S) in the wild type to proline (P) and residue 5 of CH2 (residue 248, Kabat numbering) is altered from leucine (L) in the wild type to glutamate (E).
  • DNA polymers which encode mutants or variants of the human immunoglobulin may be prepared by site-directed mutagenesis of the cDNA which codes for the required protein by conventional methods such as those described by G. Winter et al in Nature 1982, 299, 756-758 or by Zoller and Smith 1982; Nucl. Acids Res., 10, 6487-6500, or deletion mutagenesis such as described by Chan and Smith in Nucl. Acids Res., 1984, 12, 2407-2419 or by G. Winter er al in Biochem. Soc. Trans., 1984; 12, 224-225 or polymerase chain reaction such as described by Mikaelian and Sergeant in Nucleic Acids Research, 1992, 20, 376.
  • 'compound of the invention' or 'compounds of the invention' relates to the above mentioned chimera.
  • the invention provides a process for preparing a compound according to the invention which process comprises expressing DNA encoding said compound in a recombinant host cell and recovering the product.
  • the DNA polymer comprising a nucleotide sequence that encodes the compound also forms pan of the invention.
  • the process of the invention may be performed by conventional recombinant techniques such as described in Maniatis et. al., Molecular Cloning - A Laboratory Manual; Cold Spring Harbor, 1982 and DNA Cloning vols I, II and III (D.M. Glover ed., IRL Press Ltd).
  • the process may comprise the steps of: i) preparing a replicable expression vector capable, in a host cell, of expressing a
  • DNA polymer comprising a nucleotide sequence that encodes said compound; ii) transforming a host cell with said vector; iii) culturing said transformed host cell under conditions permitting expression of said DNA polymer to produce said compound; and iv) recovering said compound.
  • the invention also provides a process for preparing the DNA polymer by the condensation of appropriate mono-, di- or oligomeric nucleotide units.
  • the preparation may be carried out chemically, enzymatically, or by a combination of the two methods, in vitro or in vivo as appropriate.
  • the DNA polymer may be prepared by the enzymatic ligation of appropriate DNA fragments, by conventional methods such as those described by D. M. Robe ⁇ s et al in Biochemistry 1985, 24, 5090-5098.
  • the DNA fragments may be obtained by digestion of DNA containing the required sequences of nucleotides with appropriate restriction enzymes, by chemical synthesis, by enzymatic polymerisation on DNA or RNA templates, or by a combination of these methods.
  • Digestion with restriction enzymes may be performed in an appropriate buffer at a temperature of 20°-70°C, generally in a volume of 50 ⁇ l or less with 0.1- lO ⁇ g DNA.
  • Enzymatic polymerisation of DNA may be carried out in vitro using a DNA polymerase such as DNA polymerase I (Klenow fragment) in an appropriate buffer containing the nucleoside triphosphates dATP, dCTP, dGTP and dTTP as required at a temperature of 10°-37°C, generally in a volume of 50 ⁇ l or less.
  • a DNA polymerase such as DNA polymerase I (Klenow fragment) in an appropriate buffer containing the nucleoside triphosphates dATP, dCTP, dGTP and dTTP as required at a temperature of 10°-37°C, generally in a volume of 50 ⁇ l or less.
  • Enzymatic ligation of DNA fragments may be carried out using a DNA ligase such as T4 DNA ligase in an appropriate buffer at a temperature of 4°C to ambient, generally in a volume of 50 ⁇ l or less.
  • a DNA ligase such as T4 DNA ligase in an appropriate buffer at a temperature of 4°C to ambient, generally in a volume of 50 ⁇ l or less.
  • the chemical synthesis of the DNA polymer or fragments may be carried out by conventional phosphotriester, phosphite or phosphoramidite chemistry, using solid phase techniques such as those described in 'Chemical and Enzymatic Synthesis of Gene Fragments - A Laboratory Manual' (ed. H.G. Gassen and A. Lang), Verlag Chemie, Weinheim (1982),or in other scientific publications, for example M.J. Gait, H.W.D. Matthes, M. Singh, B.S. Sproat, and R.C. Titmas, Nucleic Acids Research, 1982, 10, 6243; B.S. Sproat and W. Bannwa ⁇ h, Tetrahedron Letters, 1983, 24, 5771; M.D.
  • the DNA polymer is preferably prepared by ligating two or more DNA molecules which together comprise a DNA sequence encoding the compound.
  • a particular process in accordance with the invention comprises ligating a first DNA molecule encoding a said leptin or variant and a second DNA molecule encoding a said immunoglobulin domain or fragment thereof.
  • the DNA molecules may be obtained by the digestion with suitable restriction enzymes of vectors carrying the required coding sequences or by use of polymerase chain reaction technology.
  • the precise structure of the DNA molecules and the way in which they are obtained depends upon the structure of the desired product.
  • the design of a suitable strategy for the construction of the DNA molecule coding for the compound is a routine matter for the skilled worker in the an.
  • the expression of the DNA polymer encoding the compound in a recombinant host cell may be carried out by means of a replicable expression vector capable, in the host cell, of expressing the DNA polymer.
  • the expression vector is novel and also forms pan of the invention.
  • the replicable expression vector may be prepared in accordance with the invention, by cleaving a vector compatible with the host cell to provide a linear DNA segment having an intact replicon, and combining said linear segment with one or more DNA molecules which, together with said linear segment, encode the compound, under ligating conditions.
  • the ligation of the linear segment and more than one DNA molecule may be carried out simultaneously or sequentially as desired.
  • the DNA polymer may be preformed or formed during the construction of the vector, as desired.
  • the choice of vector will be determined in pan by the host cell, which may be prokaryotic, such as E. coli, or eukaryotic, such as mouse C127, mouse myeloma, Chinese hamster ovary, Cosl or Hela cells, fungi e.g. filamentous fungi or unicellular yeast or an insect cell such as Drosophila.
  • the host cell may also be a transgenic animal.
  • a preferred host cell is Cosl.
  • Suitable vectors include plasmids, bacteriophages, cosmids and recombinant viruses derived from, for example, baculoviruses, vaccinia or Semliki Forest virus.
  • the preparation of the replicable expression vector may be carried out conventionally with appropriate enzymes for restriction, polymerisation and ligation of the DNA, by procedures described in, for example, Maniatis ej ai., cited above. Polymerisation and ligation may be performed as described above for the preparation of the DNA polymer. Digestion with restriction enzymes may be performed in an appropriate buffer at a temperature of 20°-70°C, generally in a volume of 50 ⁇ l or less with 0.1-10 ⁇ g DNA.
  • the recombinant host cell is prepared, in accordance with the invention, by transforming a host cell with a replicable expression vector of the invention under transforming conditions.
  • Suitable transforming conditions are conventional and are described in, for example, Maniatis et al., cited above, or "DNA Cloning" Vol. II, D.M. Glover ed., IRL Press Ltd, 1985.
  • a bacterial host such as E. coli may be treated with a solution of CaCl2 (Cohen et al, Proc. Nat. Acad. Sci., 1973, 69, 2110) or with a solution comprising a mixture of RbCl, MnCl2, potassium acetate and glycerol, and then with 3-[N-morpholino]- propane-sulphonic acid, RbCl and glycerol.
  • Mammalian cells in culture may be transformed by calcium co-precipitation of the vector DNA onto the cells.
  • the invention also extends to a host cell transformed or transfected with a replicable expression vector of the invention.
  • Culturing the transformed host cell under conditions permitting expression of the DNA polymer is carried out conventionally, as described in, for example, Maniatis et al and "DNA Cloning" cited above.
  • the cell is supplied with nutrient and cultured at a temperature below 45°C.
  • the expression product is recovered by conventional methods according to the host cell.
  • the host cell is bacterial, such as E. coli it may be lysed physically, chemically or enzymatically and the protein product isolated from the resulting lysate. If the product is to be secreted from the bacterial cell it may be recovered from the periplasmic space or the nutrient medium. Where the host cell is mammalian, the product may generally be isolated from the nutrient medium.
  • the DNA polymer may be assembled into vectors designed for isolation of stable transformed mammalian cell lines expressing the product; e.g. bovine papillomavirus vectors or amplified vectors in Chinese hamster ovary cells (DNA cloning Vol.II D.M. Glover ed. IRL Press 1985; Kaufman, R.J. ⁇ i al., Molecular and Cellular Biology 5, 1750-1759, 1985; Pavlakis G.N. and Hamer, D.H., Proceedings of the National Academy of Sciences (USA) 80, 397-401, 1983; Goeddel, DN. et al., European Patent Application No. 0093619, 1983).
  • bovine papillomavirus vectors or amplified vectors in Chinese hamster ovary cells
  • the activity of the chimeric leptin is determined by injecting it intraperitoneally, intravenously or subcutaneously into test animals such as rodents, for example mice or rats, or primates, for example rhesus monkeys.
  • test animals such as rodents, for example mice or rats, or primates, for example rhesus monkeys.
  • the test animals are preferably overweight or obese animals that have been made overweight by feeding them on a high fat or other palatable diet, or have acquired fat through the ageing process.
  • the ideal strain is the generically obese (ob/ob) mouse.
  • the effect of the active compound is seen as a reduction in food intake or increase in metabolic rate or oxygen consumption.
  • Clearance rates are determined by conventional plasma assay using ob-antibodies, for example ELISA methodology.
  • the compounds of the present invention have useful pharmaceutical prope ⁇ ies, in pa ⁇ icular anti obesity activity and also for the treatment of diseases associated with obesity, such as atherosclerosis, hype ⁇ ension and, especially, Type LI diabetes.
  • the compound will normally be employed in the form of a pharmaceutical composition in association with a human pharmaceutical carrier, diluent and/or excipient, although the exact form of the composition will depend on the mode of administration.
  • the active compound may be formulated for administration by any suitable route and is preferably in unit dosage form.
  • the composition is suitable for oral, rectal, topical, parenteral, intravenous or intramuscular administration or through the respiratory tract. Preparations may be designed to give slow release of the active ingredient.
  • compositions of the invention may be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations such as oral or sterile parenteral solutions or suspensions. Topical formulations are also envisaged where appropriate.
  • the invention therefore further provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier.
  • the dosage ranges for administration of the compounds of the present invention are those to produce the desired therapeutic effect. Dosage will generally vary with age, extent or severity of the medical condition and contraindications, if any. For example in the treatment of obsity the unit dosage can vary from less than lmg to 300mg, but typically will be in the region of 1 to 20mg per dose, in one or more doses, such as one to six doses per day, such that the daily dosage is in the range 0.02-40mg/kg. Dosages and compositions for the treatment of diseases associated with obesity such as atherosclerosis, hype ⁇ ension and, especially, Type II diabetes are selected from an equivalent range to that used in the treatment of obesity.
  • compositions suitable for injection may be in the form of solutions, suspensions or emulsions, or dry powders which are dissolved or suspended in a suitable vehicle prior to use.
  • Fluid unit dosage forms are prepared utilising the compound and a pyrogen-free sterile vehicle.
  • the compound depending on the vehicle and concentration used, can be either dissolved or suspended in the vehicle. Solutions may be used for all forms of parenteral administration, and are panicularly used for intravenous infection. In preparing solutions the compound can be dissolved in the vehicle, the solution being made isotonic if necessary by addition of sodium chloride and sterilised by filtration through a sterile filter using aseptic techniques before filling into suitable sterile vials or ampoules and sealing. Alternatively, if solution stability is adequate, the solution in its sealed containers may be sterilised by autoclaving.
  • Advantageously additives such as buffering, solubilising, stabilising, preservative or bactericidal, suspending or emulsifying agents and/or local anaesthetic agents may be dissolved in the vehicle.
  • Dry powders which are dissolved or suspended in a suitable vehicle prior to use may be prepared by filling pre-sterilised drug substance and other ingredients into a sterile container using aseptic technique in a sterile area.
  • the drug and other ingredients may be dissolved in an aqueous vehicle, the solution is sterilised by filtration and distributed into suitable containers using aseptic technique in a sterile area. The product is then freeze dried and the containers are sealed aseptically.
  • Parenteral suspensions suitable for intramuscular, subcutaneous or intradermal injection, are prepared in substantially the same manner, except that the sterile compound is suspended in the sterile vehicle, instead of being dissolved and sterilisation cannot be accomplished by filtration.
  • the compound may be isolated in a sterile state or alternatively it may be sterilised after isolation, e.g. by gamma i ⁇ adiation.
  • a suspending agent for example polyvinylpyrrolidone is included in the composition to facilitate uniform distribution of the compound.
  • compositions suitable for administration via the respiratory tract include aerosols, nebulisable solutions or microfine powders for insufflation. In the latter case, panicle size of less than 50 microns, especially less than 10 microns, is preferred. Such compositions may be made up in a conventional manner and employed in conjunction with conventional administration devices.
  • a fu ⁇ her aspect there is provided a method of treating obesity or diseases associated with obesity, such as atherosclerosis, hype ⁇ ension and, especially, Type LT diabetes, in human or non-human mammals which comprises administering to the sufferer an effective, non-toxic amount of a compound of the invention.
  • obesity or diseases associated with obesity such as atherosclerosis, hype ⁇ ension and, especially, Type LT diabetes
  • Suitable non-human mammals are domestic mammals such as dogs and cats.
  • the invention funher provides a compound of the invention for use as an active therapeutic substance, in pa ⁇ icular for use in treating obesity or diseases associated with obesity, such as atherosclerosis, hypertension and, especially, Type LT diabetes.
  • the invention also provides the use of a compound of the invention in the manufacture of a medicament for treating obesity or diseases associated with obesity, such as atherosclerosis, hype ⁇ ension and, especially, Type LT diabetes.
  • the invention also encompasses cosmetic treatments. Accordingly, there is also provided a compound of the invention for use in the cosmetic treatment of human or non-human mammals.
  • a method for the cosmetic treatment of a human or non ⁇ human mammal which treatment comprises administering an effective, non-toxic amount of a compound of the invention to a human or non-human mammal in need thereof.
  • Cosmetic treatment suitably includes treatment for the improvement of body appearence, such as weight reduction treatment.
  • compositions of the invention including cosmetic compositions are formulated using known methods, for example those described in standard text books of pharmaceutics and cosmetics, such as Harry's Cosmeticology published by Leonard Hill Books, Remington's Pharmaceutical Sciences, the British and US Pharmacopoeias.
  • the gene coding for a fusion protein comprising human leptin and the hinge-CH2-CH3 region of human IgG4 is created by recombinant DNA technology, preferably by a two-step recombinant PCR method.
  • the human Ob' gene has been prepared synthetically based on the amino acid sequence of Zhang et al, and assembled in the pcDNA3 vector.
  • the cDNA encoding full length human leptin, nucleotides 1-501 is joined at the 3' end to the 5' end of the hinge-CH2-CH3 region of the cDNA coding for the human IgG4 protein, shown as nucleotides 502-1188 in the DNA sequence below.
  • Table 1 The encoded protein sequence of the leptin/IgG4 chimera is given in Table 2.
  • Leptin 1-167 (numbering as Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold & J. Friedman. Nature 372:425-432), and IgG4 hinge-CH2-CH3 168-396 (sequence as Kabat).
  • the fusion protein was expressed transiently in Cosl cells using the pCDN vector system, as described in Intemationai Patent Application Publication number WO 96/04388.
  • the mature protein was exponed from the cells into the culture medium and was detected by anti-leptin antibody. It was shown to to have a size consistent with the predicted structure by Western blotting analysis under both reducing and nonreducing conditions.
  • DNA coding for fusion protein ob l-167/IgG4 hinge-CH2-CH3 PE variant The gene coding for a fusion protein comprising the human Ob' protein and the Hinge-CH2-CH3 region of human IgG4 PE (a form of IgG4 mutated as below) is created by recombinant DNA technology, preferably by a two-step recombinant PCR method.
  • the cDNA coding for the complete human leptin, amino acids l-167(numbering as Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold & J. Friedman. Nature 372: 425-432) is joined at the 3' end to the 5' end of the hinge-CH2-CH3 region of the cDNA coding for the human IgG4 (PE variant) protein, shown as amino acids 168-396 in the protein sequence below.
  • the human Ob' gene has been prepared synthetically based on the amino acid sequence of Zhang et al, and assembled in the pcDNA3 vector.
  • the encoded protein sequence is given in Table 2.
  • IgG4 heavy chain PE variant Human IgG4 heavy chain PE variant.
  • residue 10 of the hinge is altered from serine (S) in the wild type to proline (P) and residue 5 of CH2 (residue 248, Kabat numbering) is altered from leucine (L) in the wild type to glutamate (E).
  • Angal S. King D.J., Bodmer M.W., Turner A., Lawson A.D.G., Robe ⁇ s G., Pedley B. and Adair R., Molecular Immunology vol30ppl05-108, 1993, describe an IgG4 molecule where residue 241 (Kabat numbering) is altered from serine to proline. This change increases the serum half-life of the IgG4 molecule.
  • the IgG4 PE variant was created using PCR mutagenesis on the synthetic human IgG4 heavy chain cDNA.
  • the sequence of the IgG4 PE variant is described in Table 1.
  • the residues of the IgG4 nucleotide sequence which were altered to make the PE variant are as follows: referring to Table 1 : residue 322 has been altered to "C” in the PE variant from "T” in the wild type; residue 333 has been altered to "G” in the PE variant from "A” in the wild type; and residues 343-344 have been altered to "GA” in the PE variant from "CT” in the wild type.
  • the fusion protein was expressed transiently in Cosl cells using the pCDN vector system, as described in International Patent Application Publication number WO 96/04388.
  • the mature protein was exponed from the cells into the culture medium and was detected by anti-leptin antibody. It was shown to to have a size consistent with the predicted structure by Western blotting analysis under both reducing and nonreducing conditions.
  • Table 3 DNA sequence of IgG4 PE variant, 984bp
  • Table3A DNAsequenceofob/IgG4PEchimera, 1188bp ATGCATTGGGGAACCCTGTGCGGATTCTTGTGGCTTTGGCCCTATCTTTTCTATGTCCAA
  • the gene coding for a fusion protein comprising human leptin and the hinge-CH2-CH3 region of human IgGl is created by recombinant DNA technology, preferably by a two-step recombinant PCR method.
  • the human 'ob' gene has been prepared synthetically based on the amino acid sequence of Zhang et al, and assembled in the pcDNA3 vector.
  • the encoded protein sequence of the leptin/IgGl chimera is given in Table 2.
  • Leptin 1-167 (numbering asY. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold & J. Friedman. Nature 372: 425-432) and IgGl hinge-CH2-CH3 shown as amino acids 168-399.
  • the gene coding for the human IgGl contains a number of nucleotide substitutions compared to the IgGl molecule described by Ellison J.W., Berson B.J. and Hood L.E., Nucleic Acids Research vol 10 No. 13 pp4071-4079, 1982.
  • the IgGl nucleotides which differ from the Ellison J.W. et al published sequence and the resulting amino acid substitutions are as follows ( nucleotide numbering as in table 1)
  • nucleotide 513 is "G” in this variant compared to "T” in the Ellison et al sequence (silent mutation)
  • nucleotides 514-516 are "GCC” in this variant compared to "TGT” in the Ellison et al sequence (resulting in substitution of Ala for Cys in this variant, amino acid 172 in table 2)
  • nucleotide 759 is "T” in this variant compared to "G” in the Ellison et al sequence
  • nucleotide 924 is "G” in this variant compared to "T” in the Ellison et al sequence (resulting in substitution of Glu for Asp in this variant, amino acid 308 in table2)
  • nucleotide 928 is "A” in this variant compared to "C” in the Ellison et al sequence (resulting in substitution of Met for Val in this variant, amino acid 310 in table 2)
  • nucleotide 1077 is "T” in this variant compared to "C” in the Ellison et al sequence (silent mutation)
  • nucleotide 1197 is "G" in this variant compared to "A” in the Ellison et al sequence (silent mutation)
  • the fusion protein was expressed transiently in Cosl cells using the pCDN vector system, as described in International Patent Application Publication number WO 96/04388.
  • the mature protein was exponed from the cells into the culture medium and was detected by anti-leptin antibody. It was shown to to have a size consistent with the predicted structure by Western blotting analysis under both reducing and nonreducing conditions.
  • the gene coding for a fusion protein comprising human leptin and the hinge-CH2-CH3 region of human IgGl with a 'GT' two amino acid linker between the two parts of the fusion molecule, is created by recombinant DNA technology, preferably by a two-step recombinant PCR method.
  • the human 'ob' gene has been prepared synthetically based on the amino acid sequence of Zhang et al, and assembled in the pcDNA3 vector.
  • the cDNA encoding the full length human leptin (nucleotides 1-501) is joined at the 3' end to the 5' end of the hinge-CH2-CH3 region of the IgGl cDNA (nucleotides 508-1203).
  • the two amino acid linker between the two pans of the fusion is encoded by the nucleotide sequence GGTACC (502-507). See Table 1.
  • the encoded protein sequence of the leptin/LgG 1 (GT) chimera is given in Table 2.
  • the gene coding for the human IgGl contains a number of nucleotide substitutions compared to the IgGl molecule described by Ellison J.W., Berson B.J. and Hood L.E., Nucleic Acids Research vol 10 No. 13 pp4071-4079, 1982.
  • the IgGl nucleotides which differ from the Ellison J.W. et al published sequence and the resulting amino acid substitutions are as follows ( nucleotide numbering as in table 1)
  • nucleotide 519 is "G” in this variant compared to "T” in the Ellison et al sequence (silent mutation)
  • nucleotides 520-522 are "GCC” in this variant compared to "TGT” in the Ellison et al sequence (resulting in substitution of Ala for Cys in this variant, amino acid 174 in table 2)
  • nucleotide 759 is "T” in this variant compared to "G” in the Ellison et al sequence (silent mutation)
  • nucleotide 924 is "G” in this variant compared to "T” in the Ellison et al sequence (resulting in substitution of Glu for Asp in this variant, amino acid 308 in table2)
  • nucleotide 928 is "A” in this variant compared to "C” in the Ellison et al sequence (resulting in substitution of Met for Val in this variant, amino acid 310 in table 2)
  • nucleotide 1077 is "T” in this variant compared to "C” in the Ellison et al sequence
  • nucleotide 1197 is "G" in this variant compared to "A” in the Ellison et al sequence
  • the fusion protein was expressed transiently in Cosl cells using the pCDN vector system, as described in International Patent Application Publication number WO 96/04388.
  • the mature protein was exponed from the cells into the culture medium and was detected by anti-leptin antibody. It was shown to to have a size consistent with the predicted structure by Westem blotting analysis under both reducing and nonreducing conditions.
  • VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne de la leptine chimérisée, à savoir des protéines comprenant de la leptine, l'un de ses mutants, ou l'une de ses variantes, fusionnées à un domaine d'immunoglobuline humaine. L'un des domaines préférés d'immunoglobuline est le domaine Fc de l'immunoglobuline humaine. Malgré leur grande taille moléculaire, ces dérivés chimériques de la leptine présentent une bonne activité pharmacologique combinée à des durées élevées d'élimination par l'organisme. Ces dérivés de leptine conviennent donc particulièrement pour le traitement ou la prophylaxie de l'obésité ou des affections et états associés à l'obésité tels que l'athérosclérose, l'hypertension et le diabète de type II.
EP96917584A 1995-06-13 1996-06-11 Leptine chimirasee par fusion avec un domaine d'immunoglobuline et utilisation correspondante Withdrawn EP0832219A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9511935 1995-06-13
GBGB9511935.0A GB9511935D0 (en) 1995-06-13 1995-06-13 Novel compound
PCT/GB1996/001388 WO1997000319A2 (fr) 1995-06-13 1996-06-11 Leptine chimirasee par fusion avec un domaine d'immunoglobuline et utilisation correspondante

Publications (1)

Publication Number Publication Date
EP0832219A2 true EP0832219A2 (fr) 1998-04-01

Family

ID=10775951

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96917584A Withdrawn EP0832219A2 (fr) 1995-06-13 1996-06-11 Leptine chimirasee par fusion avec un domaine d'immunoglobuline et utilisation correspondante

Country Status (6)

Country Link
EP (1) EP0832219A2 (fr)
JP (1) JPH11507547A (fr)
AU (1) AU6011096A (fr)
CA (1) CA2224646A1 (fr)
GB (1) GB9511935D0 (fr)
WO (1) WO1997000319A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291458B2 (en) 1998-07-28 2007-11-06 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Leptin-mediated gene-induction

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310034B1 (en) 1993-05-21 2001-10-30 Ut-Battelle, Llc Agouti polypeptide compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
PT866720E (pt) * 1995-11-22 2004-06-30 Amgen Inc Proteina ob para aumentar a massa do tecido mole
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
AU769250B2 (en) * 1995-12-27 2004-01-22 Genentech Inc. OB protein derivatives having prolonged half-life
IL124831A0 (en) * 1995-12-27 1999-01-26 Genentech Inc Ob protein derivatives having prolonged half-life
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
CA2275183A1 (fr) * 1996-12-20 1998-07-02 Amgen Inc. Procedes et compositions de proteines de fusion ob
AU770897B2 (en) * 1996-12-20 2004-03-04 Amgen, Inc. OB fusion protein compositions and methods
AU6656098A (en) * 1997-02-25 1998-09-09 Eli Lilly And Company Treatment of infertility with leptin receptor ligands
AU2002300605B8 (en) * 1997-04-17 2006-02-09 Amgen Inc. Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods
ATE223229T1 (de) * 1997-04-17 2002-09-15 Amgen Inc Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
US6187564B1 (en) 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6242570B1 (en) 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
AU8182298A (en) * 1997-07-10 1999-02-08 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
HUP0100813A3 (en) * 1998-02-25 2003-08-28 Lexigen Pharmaceuticals Corp L Enhancing the circulating half-life of antibody-based fusion proteins
HUP0105090A2 (hu) * 1999-01-07 2002-04-29 Lexigen Pharmaceuticals Corporation Kóros elhízás elleni fehérjék expressziója és exportja Fc fúziós fehérje formájában
MXPA01011264A (es) * 1999-05-07 2002-07-02 Genentech Inc Nuevos polipeptidos de eritropoyetina de chimpance (chepo) y aciodos nucleicos que codifican los mismos.
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es) 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
WO2001025428A1 (fr) * 1999-10-01 2001-04-12 Eli Lilly And Company Nouvel homologue humain de la leptine
CA2391080A1 (fr) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Formes d'erythropoietine dotees de proprietes ameliorees
HUP0204475A2 (en) * 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
EP1283878B1 (fr) 2000-05-22 2005-07-27 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Piege a interaction base sur des recepteurs
KR20030064275A (ko) 2000-06-29 2003-07-31 메르크 파텐트 게엠베하 면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
US7235629B2 (en) 2000-11-14 2007-06-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Functional fragment of the leptin receptor
CN100522242C (zh) * 2001-02-19 2009-08-05 默克专利有限公司 具有降低的免疫原性的人工蛋白质
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
WO2002079415A2 (fr) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reduction de l'immunogenicite de proteines de fusion
EP1383785B1 (fr) 2001-05-03 2011-03-16 Merck Patent GmbH Anticorps recombine a specificite tumorale et utilisation correspondante
DK1454138T3 (da) 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
WO2004055056A1 (fr) 2002-12-17 2004-07-01 Merck Patent Gmbh Forme humanisee de l'anticorps de souris 14.18 (h14.18) se liant au gd2 et fusion de celle-ci avec il-2
ATE385806T1 (de) * 2003-06-12 2008-03-15 Lilly Co Eli Fusionsproteine
DK1641823T3 (da) 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
WO2005037867A1 (fr) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Modification de demi-vies seriques de proteines de fusion fc par mutagenese de positions 250, 314 et/ou 428 de la region constante de la chaine lourde des immunoglobulines
ES2383300T3 (es) 2003-11-13 2012-06-20 Hanmi Holdings Co., Ltd Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
ES2305886T3 (es) 2003-12-30 2008-11-01 Merck Patent Gmbh Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
EP1702069A2 (fr) 2004-01-05 2006-09-20 EMD Lexigen Research Center Corp. Interleukine-12 ciblee sur la fibronectine oncofoetale
US7423113B2 (en) 2004-08-25 2008-09-09 Vib Vzw Leptin antagonist
EP1812038A1 (fr) 2004-11-18 2007-08-01 VIB vzw Domaine de fibronectine iii servant d'antagonistes de recepteurs de la leptine
RU2437893C2 (ru) 2004-12-09 2011-12-27 Мерк Патент Гмбх Варианты il-7 со сниженной иммуногенностью
DK1831252T3 (da) * 2004-12-22 2009-10-05 Lilly Co Eli GLP-1 analog fusionsproteinformuleringer
EP2441838A3 (fr) * 2006-01-24 2013-07-10 Domantis Limited Protéines de fusion contenant des jonctions naturelles
US20100047171A1 (en) * 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
SG175233A1 (en) 2009-04-22 2011-11-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0464533T3 (da) * 1990-06-28 1999-04-26 Gen Hospital Corp Fusionsproteiner med immunglobulindele, deres fremstilling og anvendelse
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9509164D0 (en) * 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
AU5737696A (en) * 1995-05-08 1996-11-29 Chiron Corporation Nucleic acids for treating obesity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9700319A2 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291458B2 (en) 1998-07-28 2007-11-06 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Leptin-mediated gene-induction

Also Published As

Publication number Publication date
AU6011096A (en) 1997-01-15
WO1997000319A2 (fr) 1997-01-03
WO1997000319A3 (fr) 1997-04-10
GB9511935D0 (en) 1995-08-09
CA2224646A1 (fr) 1997-01-03
JPH11507547A (ja) 1999-07-06

Similar Documents

Publication Publication Date Title
EP0832219A2 (fr) Leptine chimirasee par fusion avec un domaine d'immunoglobuline et utilisation correspondante
KR102219124B1 (ko) 비글리코실화 Fc-함유 폴리펩티드
EP1606318B1 (fr) Proteines hybrides fc ameliorees
US5783181A (en) Therapeutic uses of fusion proteins between mutant IL 4/IL13 antagonists and immunoglobulins
EP2507267B1 (fr) Compositions et procédés pour augmenter la demi-vie sérique de protéines de fusion fc
CA2781539C (fr) Anticorps monomere fc
AU720943B2 (en) Receptor protein designated 2F1
EP0770135A1 (fr) Nouveaux composes
KR20160034404A (ko) Ｆc-함유 폴리펩타이드의 안정화
JPH06315383A (ja) Ｃｄ４０のための可溶性リガンド
JPH08507676A (ja) 可溶性オリゴマー蛋白質の調製法
JPH0753594A (ja) インターロイキン−１２のｐ４０ホモダイマー
NZ260146A (en) Tumour necrosis factor (tnfalpha) muteins and their production and use
CN101014626A (zh) 糖基化免疫球蛋白以及含有糖基化免疫球蛋白的免疫粘附素
KR19990063653A (ko) 케모킨 억제제
WO2022117044A1 (fr) Polypeptide agoniste du récepteur double glp-1/gcg et sa protéine de fusion
AU2022263441A1 (en) Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof
CA2339968A1 (fr) Dcr5, proteine de fixation de proteines morphogenetiques osseuses, et ses applications
EP0636175A1 (fr) Fragments de decorine et procede d'inhibition de facteurs de regulation cellulaire
US20240101627A1 (en) Mhc class ii t-cell modulatory polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
KR100418329B1 (ko) 직렬 연쇄체를 갖는 면역접합체
AU2140699A (en) Novel compounds
AU1196402A (en) Novel compounds
EP0904293A1 (fr) Antagoniste d'interleukine-5
BR112015023145B1 (pt) Polipeptídeos contendo fc aglicosilados e anticorpo ou proteína de fusão fc

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971216

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): BE CH DE DK ES FR GB IT LI NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030103